The N125S polymorphism in the cathepsin G gene (rs45567233) is associated with susceptibility to osteomyelitis in a Spanish population

English version

Autoři: Laura Pérez-Is ^aff001; Marcos G. Ocaña ^aff003; A. Hugo Montes ^aff001; José A. Carton ^aff002; Victoria Álvarez ^aff005; Álvaro Meana ^aff006; Joshua Fierer ^aff007; Eulalia Valle-Garay ^aff001; Víctor Asensi ^aff002
Působiště autorů: Biochemistry and Molecular Biology, University Medical School, Oviedo, Spain ^aff001; Group of Translational Research in Infectious Diseases, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain ^aff002; Biotechnological and Biomedical Assays Unit, University Medical School Oviedo, Spain ^aff003; Infectious Diseases, Hospital Universitario Central de Asturias, University Medical School, Oviedo, Spain ^aff004; Molecular Genetics Unit-Nephrology Research Institute, Hospital Universitario Central de Asturias, Oviedo, Spain ^aff005; Community Center for Blood and Tissues of Asturias, CIBERER U714, Oviedo, Spain ^aff006; Infectious Diseases Section, VAMC and University of California, San Diego, California, United States of America ^aff007
Vyšlo v časopise: PLoS ONE 14(10)
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pone.0220022

Souhrn

Background

Osteomyelitis is a bone infection, most often caused by Staphylococcus aureus, in which neutrophils play a key role. Cathepsin G (CTSG) is a bactericidal serine protease stored in the neutrophil azurophilic granules. CTSG regulates inflammation, activating matrix metalloproteinases (MMPs), and coagulation. Lactoferrin (LF), a neutrophil glycoprotein, increases CTSG catalytic activity and induces inflammation. The aim of this study was to analyze a potential association between a CTSG gene polymorphism (Asn125Ser or N125S, rs45567233), that modifies CTSG activity, and could affect susceptibility to, or outcome of, bacterial osteomyelitis.

Methods

CTSG N125S polymorphism was genotyped in 329 osteomyelitis patients and 415 controls), Blood coagulation parameters, serum CTSG activity, LF, MMP-1, MMP-13, and soluble receptor activator for nuclear factor κ B ligand (sRANKL) levels were assessed in carriers of the different CTSG genotypes.

Results

CTSG N125S (AG) genotype was significantly more frequent among osteomyelitis patients than controls (15.5% vs. 9.4%, p = 0.014). CTSG N125S variant G allele (AG +GG) was also more frequent among osteomyelitis patients (8.1% vs. 4.7%, p = 0.01). Serum CTSG activity and LF levels were significantly higher in osteomyelitis patients carrying the G allele compared to those with the AA genotype, (p<0.04). Serum MMP-1 was lower in the G allele carriers (p = 0.01). There was no association between these genotypes and clinical characteristics of osteomyelitis, or coagulation parameters, MMP-13, and sRANKL serum levels.

Conclusions

Differences in the CTSG gene might enhance osteomyelitis susceptibility by increasing CTSG activity and LF levels.

Klíčová slova:

Heredity – Alleles – Inflammation – Inflammatory diseases – Variant genotypes – Neutrophils – Osteomyelitis – Staphylococcal infection

Zdroje

1. Korkmarz B, Moreau T, Gauthier F. Neutrophil elastase, proteinase 3 and cathepsin G: Physicochemical properties, activity and physiopathological functions. Biochemie 2008; 90: 227–242.

2. Korkmaz B, Horwitz MS, Jenne DE, Gauthier F. Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. Pharmacol Rev 2010; 62: 726–759. doi: 10.1124/pr.110.002733 21079042

3. Sambrano GR, Huang W, Faruqui T, Mahrus S, Craik C, Coughlin SR. Cathepsin G activates protease-activated receptor-4 in human platelets. J Biol Chem. 2000; 275:6819–6823. doi: 10.1074/jbc.275.10.6819 10702240

4. Wilson TJ, Nananuru KC, Futakuchi M, Sadanandam, Singh RK. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-κB ligand. Cancer Res 2008; 68: 5803–5811. doi: 10.1158/0008-5472.CAN-07-5889 18632634

5. Ludecke B, Poler W, Olek K, Bartholome K. Sequence variant of the human cathepsin G gene. Hum Genet 1993; 91:83–84. doi: 10.1007/bf00230230 8454293

6. Hermann SM, Funke-Kaiser H, Schmidt-Petersen K, Nicaud V, Gautier-Bertrand M, Evans A, et al. Characterization of polymorphic structure of cathepsin G. Role in cardiovascular and cerebrovascular diseases. Arterioscler Thromb Vasc Biol 2001, 21: 1538–1543. doi: 10.1161/hq0901.095555 11557685

7. Sipahi T, Pocan H, Akar N. Efect of various genetic polymorphism on the incidence and outcome of severe sepsis. Clin Appl Thrombosis/Hemostasis 2006; 12: 47–54.

8. Eipper S, Steiner R, Lesner A, Syenczyk M, Palesch D, Halatsch M-E, et al. Lactoferrin is an allosteric enhancer of the proteolytic activity of cathepsin G. PLoS ONE 2016 11: e0151509. doi: 10.1371/journal.pone.0151509 26986619

9. Komine K, Kuroishi T, Ozawa A, Komine Y, Minami T, Shimauchi H, et al. Cleaved inflammatory lactoferrin peptides in parotid saliva of periodontitis patients. Mol Immunol 2007; 44: 1498–1508. doi: 10.1016/j.molimm.2006.09.003 17030385

10. Lew D, Waldvogel FA. Osteomyelitis. Lancet 2004; 364:369–379. doi: 10.1016/S0140-6736(04)16727-5 15276398

11. Asensi V, Valle E, Meana A, Fierer J, Celada A, Alvarez V, et al. In vivo interleukin-6 protects neutrophils from apoptosis in osteomyelitis. Infect Immun. 2004; 72:3823–8. doi: 10.1128/IAI.72.7.3823-3828.2004 15213123

12. García del Pozo E, Collazos J, Carton JA, Camporro D, Asensi. Bacterial osteomyelitis: microbiological, clinical, therapeutic, and evolutive characteristics of 344 episodes. Rev Esp Quimioter 2018; 31:217–225. 29756429

13. Ocaña MG, Asensi V, Montes AH, Meana A, Celada A, Valle-Garay E Autoregulation mechanism of human neutrophil apoptosis during bacterial infection. Mol Immunol 2008; 45:2087–96. doi: 10.1016/j.molimm.2007.10.013 18022234

14. Asensi V, Alvarez V, Valle E, Meana A, Fierer J, Coto E, et al. IL-1 alpha (-889) promoter polymorphism is a risk factor for osteomyelitis. Am J Med Genet 2003;119A:132–136. doi: 10.1002/ajmg.a.20137 12749050

15. Montes AH, Asensi V, Alvarez V, Meana A, Fierer J, Meana A, et al. The Toll-like receptor 4 (Asp299Gly) polymorphism is a risk factor for Gram-negative and haematogenous osteomyelitis. Clin Exp Immunol 2006; 143:404–413. doi: 10.1111/j.1365-2249.2005.03002.x 16487238

16. Asensi V, Montes AH, Valle E, Ocaña MG, Astudillo A, Alvarez V, et al. The NOS3 (27-bp repeat, intron 4) polymorphism is associated with susceptibility to osteomyelitis. Nitric Oxide 2007: 16:44–53. doi: 10.1016/j.niox.2006.06.005 16889995

17. Ocaña MG, Valle-Garay E, Montes AH, Meana A, Cartón JA, Fierer J, et al. Bax gene (-248)G/A promoter polymorphism is associated with increased lifespan of the neutrophils of patients with osteomyelitis. Genet Med 2007; 9:249–255. doi: 10.1097GIM.0b013e318039b23d 17438390

18. Montes AH, Valle-Garay E, Alvarez V, Pevida M, García Pérez E, Paz J, et al. A functional polymorphism in MMP1 could influence osteomyelitis development. J Bone Miner Res 2010; 25:912–919. doi: 10.1359/jbmr.091013 19821768

19. Valle-Garay E, Montes AH, Corte JR, Meana A, Fierer J, Asensi V. tPA Alu (I/D) polymorphism associates with bacterial osteomyelitis. J Infect Dis 2013; 208: 218–223. doi: 10.1093/infdis/jit158 23570848

20. Bhojak TJ, DeKosjky ST, Ganguli M, Kamboh MI. Genetic polymorphism in the cathepsin G gene and the risk of Alzheimer’s disease. Neurosci Lett 2001; 309: 138–140. doi: 10.1016/s0304-3940(01)02033-x 11502364

21. Senior RM, Campbell EJ. Cathepsin G in human mononuclear phagocytes: comparisons between monocytes and U937 monocyte-like cells. J Immunol 1984; 1432: 2547–2551.

22. Funke-Kaiser H., Orzechowski H-D, Richter M, Paul M. Human endothelin-converting enzyme -1* (ECE-1*) mRNA expression is regulated by an alternative promoter. J Cardiovasc Pharmacol 1998; 31: S7–S9. doi: 10.1097/00005344-199800001-00004 9595385

23. Behague I, Poirier O, Nicaud V, Evans A, Arveiler D, Luc G, et al. Beta-fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction: the ECTIM Study. Circulation 1996; 93: 440–449.

24. Son ED, Kim H, Choi H, Lee SH, Lee JY, Kim S. CTSG increases MMP expression in normal human fibroblasts through fibronectine fragmentation, and induces the conversion of proMMP-1 to active MMP-1. J Dermatol Sci 2009; 53: 150–152. doi: 10.1016/j.jdermsci.2008.08.006 18835135

25. Okada Y, Nakanishi I. Activation of matrix metalloproteinase 3 (stromelysin) and matrix metalloproteinase 2 (“gelatinase”) by human neutrophil elastase and cathepsin G. FEBS Lett 1989; 2: 353–356.

26. Wilson TJ, Nannuru KC, Singh RK. Cathepsin G-mediated activation of pro-matrix metalloproteinase 9 at tumor-bone interface promotes transforming growth factor-β signalling and bone destruction. Mol Cancer Res 2009; 7:1224–1233. doi: 10.1158/1541-7786.MCR-09-0028 19671689

27. Abbott RE, Corral CJ, MacIvor DM, Lin, Ley TJ, Mustoe TA. Augmented inflammatory responses and altered wound healing in cathepsin G-deficient mice. Arch Surg 1998; 133: 1002–1006. doi: 10.1001/archsurg.133.9.1002 9749856